These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 11097863)

  • 1. Highly potent nociceptin analog containing the Arg-Lys triple repeat.
    Okada K; Sujaku T; Chuman Y; Nakashima R; Nose T; Costa T; Yamada Y; Yokoyama M; Nagahisa A; Shimohigashi Y
    Biochem Biophys Res Commun; 2000 Nov; 278(2):493-8. PubMed ID: 11097863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discriminatory synergistic effect of Trp-substitutions in superagonist [(Arg/Lys)(14), (Arg/Lys)(15)]nociceptin on ORL1 receptor binding and activation.
    Nishimura H; Li J; Isozaki K; Okada K; Matsushima A; Nose T; Costa T; Shimohigashi Y
    Bioorg Med Chem; 2009 Aug; 17(15):5683-7. PubMed ID: 19577933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spare interactions of highly potent [Arg(14),Lys(15)]nociceptin for cooperative induction of ORL1 receptor activation.
    Isozaki K; Li J; Okada K; Nishimura H; Matsushima A; Nose T; Costa T; Shimohigashi Y
    Bioorg Med Chem; 2009 Dec; 17(23):7904-8. PubMed ID: 19879767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effect of basic residues at positions 14-15 of nociceptin on binding affinity and receptor activation.
    Okada K; Isozaki K; Li J; Matsushima A; Nose T; Costa T; Shimohigashi Y
    Bioorg Med Chem; 2008 Oct; 16(20):9261-7. PubMed ID: 18818087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-activity studies on nociceptin analogues: ORL1 receptor binding and biological activity of cyclic disulfide-containing analogues of nociceptin peptides.
    Ambo A; Hamazaki N; Yamada Y; Nakata E; Sasaki Y
    J Med Chem; 2001 Nov; 44(23):4015-8. PubMed ID: 11689089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological studies of nociceptin derivatives containing the DTPA chelating group for further labeling with therapeutic radionuclides.
    Ligeti M; Gündüz O; Magyar A; Kató E; Rónai AZ; Vita C; Varga I; Hudecz F; Tóth G; Borsodi A; Benyhe S
    Peptides; 2005 Jul; 26(7):1159-66. PubMed ID: 15949634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A structure-activity study of nociceptin-(1-13)-peptide amide. Synthesis of analogues substituted in positions 0, 1, 3, 4 and 10.
    Bobrova I; Vlaskovska M; Kasakov L; Surovoy A; Egorova N; Johansson L; Karsnas P; Terenius L
    Eur J Med Chem; 2003; 38(7-8):687-94. PubMed ID: 12932899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a hexapeptide binding region in the nociceptin (ORL1) receptor by photo-affinity labelling with Ac-Arg-Bpa-Tyr-Arg-Trp-Arg-NH2.
    Bes B; Meunier JC
    Biochem Biophys Res Commun; 2003 Oct; 310(3):992-1001. PubMed ID: 14550303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides.
    Lapalu S; Moisand C; Mazarguil H; Cambois G; Mollereau C; Meunier JC
    FEBS Lett; 1997 Nov; 417(3):333-6. PubMed ID: 9409745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural requirements of nociceptin antagonist Ac-RYYRIK-NH2 for receptor binding.
    Kawano C; Okada K; Honda T; Nose T; Sakaguchi K; Costa T; Shimohigashi Y
    J Pept Sci; 2002 Oct; 8(10):561-9. PubMed ID: 12450325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular modelling of the ORL1 receptor and its complex with nociceptin.
    Topham CM; Moulédous L; Poda G; Maigret B; Meunier JC
    Protein Eng; 1998 Dec; 11(12):1163-79. PubMed ID: 9930666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the high affinity [3H]nociceptin binding site in membrane preparations of rat heart: correlations with the non-opioid dynorphin binding site.
    Dumont M; Lemaire S
    J Mol Cell Cardiol; 1998 Dec; 30(12):2751-60. PubMed ID: 9990545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Address and message sequences for the nociceptin receptor: a structure-activity study of nociceptin-(1-13)-peptide amide.
    Guerrini R; Calo G; Rizzi A; Bianchi C; Lazarus LH; Salvadori S; Temussi PA; Regoli D
    J Med Chem; 1997 Jun; 40(12):1789-93. PubMed ID: 9191955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity study of the ORL1 antagonist Ac-Arg-D-Cha-Qaa-D-Arg-D-p-ClPhe-NH2.
    Van Cauwenberghe S; Simonin F; Cluzeau J; Becker JA; Lubell WD; Tourwé D
    J Med Chem; 2004 Mar; 47(7):1864-7. PubMed ID: 15027881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solution conformation of nociceptin.
    Salvadori S; Picone D; Tancredi T; Guerrini R; Spadaccini R; Lazarus LH; Regoli D; Temussi PA
    Biochem Biophys Res Commun; 1997 Apr; 233(3):640-3. PubMed ID: 9168905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationships of dynorphin analogs substituted in positions 2 and 3.
    Schlechtingen G; DeHaven RN; Daubert JD; Cassel J; Goodman M
    Biopolymers; 2003; 71(1):71-6. PubMed ID: 12712501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward understanding the cationicity of defensins. Arg and Lys versus their noncoded analogs.
    Zou G; de Leeuw E; Li C; Pazgier M; Li C; Zeng P; Lu WY; Lubkowski J; Lu W
    J Biol Chem; 2007 Jul; 282(27):19653-65. PubMed ID: 17452329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity.
    Kohn WD; Micanovic R; Myers SL; Vick AM; Kahl SD; Zhang L; Strifler BA; Li S; Shang J; Beals JM; Mayer JP; DiMarchi RD
    Peptides; 2007 Apr; 28(4):935-48. PubMed ID: 17328992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective cytotoxicity following Arg-to-Lys substitution in tritrpticin adopting a unique amphipathic turn structure.
    Yang ST; Shin SY; Lee CW; Kim YC; Hahm KS; Kim JI
    FEBS Lett; 2003 Apr; 540(1-3):229-33. PubMed ID: 12681513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activity of nociceptin/orphanin FQ(1-13)NH2 analogues modified in 9 and/or 13 position.
    Naydenova ED; Zhivkova VI; Zamfirova RN; Vezenkov LT; Dobrinova YG; Mateeva PI
    Bioorg Med Chem Lett; 2006 Aug; 16(15):4071-4. PubMed ID: 16714110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.